Ovid Q2 2026: $15M Net Loss, $169.8M Cash, and New Financing Details
OVID has more than doubled off its 52-week low of $0.534.
Summary
Ovid Therapeutics reported a $15.0M Q2 net loss with $169.8M in cash, and disclosed new details on recent financings and pipeline progress.
Key Events · Earnings and Guidance · OVID
-
Q2 Net Loss of $15.0M
Net loss was $15.0 million for Q2 2026, up from $4.7 million in Q2 2025, driven by a 54% increase in R&D spending to $10.0 million.
-
Cash Runway Extended
Cash, cash equivalents, and marketable securities totaled $169.8 million as of June 30, 2026, sufficient to fund operations for at least 12 months.
-
March 2026 Private Placement Details
The company sold 19,154,321 shares at $2.01 per share and pre-funded warrants for 10,701,710 shares at $2.009, raising $56.2 million net.
-
July 2026 ATM Sale
On July 23, 2026, Ovid sold 3.5 million shares at $2.38 per share for $8.3 million gross proceeds, leaving $64.3 million available under the ATM program.
Analysis · OVID · Life Sciences
Ovid reported a $15.0 million net loss for Q2 2026, but the balance sheet shows $169.8 million in cash and marketable securities, extending its runway through at least the next 12 months. The 10-Q also reveals the full terms of the March 2026 private placement and a July 2026 ATM sale, providing clarity on recent dilution. The company's pipeline is advancing, with OV329 and OV4071 driving a 54% increase in R&D spending year-over-year.
At the time of this filing, OVID was trading at $2.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $489M. The 52-week trading range was $0.53 to $3.11. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.